Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?
Ivana FridrichovaLenka KalinkovaSona CiernikovaPublished in: International journal of molecular sciences (2022)
Metastatic breast cancer (MBC) is typically an incurable disease with high mortality rates; thus, early identification of metastatic features and disease recurrence through precise biomarkers is crucial. Circulating tumor cells (CTCs) consisting of heterogeneous subpopulations with different morphology and genetic, epigenetic, and gene expression profiles represent promising candidate biomarkers for metastatic potential. The experimentally verified role of epithelial-to-mesenchymal transition in cancer dissemination has not been clearly described in BC patients, but the stemness features of CTCs strongly contributes to metastatic potency. Single CTCs have been shown to be protected in the bloodstream against recognition by the immune system through impaired interactions with T lymphocytes and NK cells, while associations of heterotypic CTC clusters with platelets, leucocytes, neutrophils, tumor-associated macrophages, and fibroblasts improve their tumorigenic behavior. In addition to single CTC and CTC cluster characteristics, we reviewed CTC evaluation methods and clinical studies in early and metastatic BCs. The variable CTC tests were developed based on specific principles and strategies. However, CTC count and the presence of CTC clusters were shown to be most clinically relevant in existing clinical trials. Despite the known progress in CTC research and sampling of BC patients, implementation of CTCs and CTC clusters in routine diagnostic and treatment strategies still requires improvement in detection sensitivity and precise molecular characterizations, focused predominantly on the role of CTC clusters for their higher metastatic potency.
Keyphrases
- circulating tumor cells
- circulating tumor
- squamous cell carcinoma
- small cell lung cancer
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- stem cells
- chronic kidney disease
- metastatic breast cancer
- primary care
- healthcare
- prognostic factors
- dna methylation
- gene expression
- induced apoptosis
- type diabetes
- copy number
- bone marrow
- escherichia coli
- genome wide
- oxidative stress
- cardiovascular events
- climate change
- signaling pathway
- cell proliferation
- clinical practice
- coronary artery disease
- cell death
- papillary thyroid
- loop mediated isothermal amplification
- klebsiella pneumoniae
- patient reported
- phase ii
- phase iii
- childhood cancer